Published in Brain on June 24, 2016
Safety and improvement of movement function after stroke with atomoxetine: A pilot randomized trial. Restor Neurol Neurosci (2016) 0.75
Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects. NPJ Parkinsons Dis (2017) 0.75
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage (2006) 23.57
Dynamic causal modelling. Neuroimage (2003) 17.17
Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage (2008) 12.12
Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord (2010) 9.34
Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci (2003) 5.94
Bayesian model selection for group studies. Neuroimage (2009) 5.46
Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science (2007) 4.57
About "axial" and "radial" diffusivities. Magn Reson Med (2009) 4.13
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 3.79
Identifying neural drivers with functional MRI: an electrophysiological validation. PLoS Biol (2008) 3.41
False discovery rate revisited: FDR and topological inference using Gaussian random fields. Neuroimage (2008) 3.38
Comparing families of dynamic causal models. PLoS Comput Biol (2010) 3.38
Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res (2002) 3.34
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci (2010) 3.05
Ten simple rules for dynamic causal modeling. Neuroimage (2009) 2.83
Inhibition and the right inferior frontal cortex: one decade on. Trends Cogn Sci (2014) 2.62
Executive "brake failure" following deactivation of human frontal lobe. J Cogn Neurosci (2006) 2.44
Functional connectivity delineates distinct roles of the inferior frontal cortex and presupplementary motor area in stop signal inhibition. J Neurosci (2009) 2.36
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Nonlinear dynamic causal models for fMRI. Neuroimage (2008) 2.13
The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) (2008) 2.07
Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci (2012) 1.98
Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry (2008) 1.89
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry (2007) 1.82
Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition. Neurosci Biobehav Rev (2009) 1.74
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2014) 1.70
Broca's region: novel organizational principles and multiple receptor mapping. PLoS Biol (2010) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Analysing connectivity with Granger causality and dynamic causal modelling. Curr Opin Neurobiol (2012) 1.60
Effects of norepinephrine and glyceryl trinitrate on cerebral haemodynamics: transcranial Doppler study in healthy volunteers. Br J Anaesth (2008) 1.60
A computational model of inhibitory control in frontal cortex and basal ganglia. Psychol Rev (2013) 1.60
Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet (2005) 1.55
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging (2007) 1.50
Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol (2010) 1.30
Free energy, precision and learning: the role of cholinergic neuromodulation. J Neurosci (2013) 1.27
Tractography-based priors for dynamic causal models. Neuroimage (2009) 1.25
Cortico-subthalamic white matter tract strength predicts interindividual efficacy in stopping a motor response. Neuroimage (2011) 1.24
Prefrontal and monoaminergic contributions to stop-signal task performance in rats. J Neurosci (2011) 1.17
Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage (2010) 1.17
Bayesian model selection for group studies - revisited. Neuroimage (2013) 1.16
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord (2009) 1.16
The role of the subthalamic nucleus in response inhibition: evidence from local field potential recordings in the human subthalamic nucleus. Neuroimage (2011) 1.15
Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem (1998) 1.14
Deep brain stimulation of subthalamic nuclei affects arm response inhibition in Parkinson's patients. Cereb Cortex (2011) 1.14
Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol (2007) 1.14
Connectivity Analysis is Essential to Understand Neurological Disorders. Front Syst Neurosci (2010) 1.13
Aging and inhibitory control of action: cortico-subthalamic connection strength predicts stopping performance. J Neurosci (2012) 1.10
Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity. Brain (2014) 1.10
White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage (2012) 1.04
Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res (2011) 1.00
The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol (2014) 0.99
Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex (2012) 0.97
Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD. Psychopharmacology (Berl) (2013) 0.97
Dopamine transporter genotype predicts behavioural and neural measures of response inhibition. Mol Psychiatry (2011) 0.94
The prefrontal cortex achieves inhibitory control by facilitating subcortical motor pathway connectivity. J Neurosci (2015) 0.94
The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci (2012) 0.93
Selection and stopping in voluntary action: a meta-analysis and combined fMRI study. Neuroimage (2013) 0.93
The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol (2014) 0.93
Noradrenergic enhancement improves motor network connectivity in stroke patients. Ann Neurol (2010) 0.92
Improving response inhibition in Parkinson's disease with atomoxetine. Biol Psychiatry (2014) 0.91
Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. Exp Brain Res (2011) 0.90
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain (2014) 0.89
Multiple modes of impulsivity in Parkinson's disease. PLoS One (2014) 0.87
Age-related changes in causal interactions between cortical motor regions during hand grip. Neuroimage (2011) 0.86
Reversed frontotemporal connectivity during emotional face processing in remitted depression. Biol Psychiatry (2012) 0.85
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85
Dopamine D₂ receptor modulation of human response inhibition and error awareness. J Cogn Neurosci (2012) 0.85
Dopaminergic drug effects during reversal learning depend on anatomical connections between the orbitofrontal cortex and the amygdala. Front Neurosci (2013) 0.84
Dopaminergic modulation of motor network dynamics in Parkinson's disease. Brain (2015) 0.84
Targeting impulsivity in Parkinson's disease using atomoxetine. Brain (2014) 0.84
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain (2015) 0.84
Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med (2014) 0.83
Parkinson's disease and healthy aging: independent and interacting effects on action selection. Hum Brain Mapp (2010) 0.83
Perseveration and choice in Parkinson's disease: the impact of progressive frontostriatal dysfunction on action decisions. Cereb Cortex (2012) 0.82
Effective connectivity within human primary visual cortex predicts interindividual diversity in illusory perception. J Neurosci (2013) 0.81
White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations. Mov Disord (2013) 0.80
Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function. Psychopharmacology (Berl) (2013) 0.80
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Hum Brain Mapp (2016) 0.79
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease. Neuropsychopharmacology (2016) 0.78
Profiling neuronal ion channelopathies with non-invasive brain imaging and dynamic causal models: Case studies of single gene mutations. Neuroimage (2015) 0.76